Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
A pill bottle on an office desk with a data chart in the background.

Jun 9, 2026

From Dashboards to Decisions: How AI Is Reshaping Pharma Brand Strategy

The integration of AI into pharmaceutical brand strategy is transforming decision-making processes, enabling faster and more effective responses to market dynamics.In the rapidly evolving life sciences sector, pharmaceutical brand leaders face unprecedented challenges due to heightened competition and shifting economic policies. As organizations increasingly rely on data analytics, the focus has shifted from merely collecting data to utilizing AI-driven insights for swift decision-making. This t
A minimalist representation of a stock certificate with a share icon.

Jun 9, 2026

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time

Shuttle Pharmaceuticals Holdings, Inc. has announced a reverse stock split scheduled for June 11, 2026, aiming to strengthen its capital structure and comply with Nasdaq listing requirements.The Gaithersburg-based company will implement a 10-for-1 reverse stock split, reducing its outstanding shares from approximately 6.37 million to around 637,108. This adjustment will also affect shares associated with various equity instruments, including RSUs and warrants. Following the split, Shuttle Pharma
A vaccine vial and syringe in a dimly lit lab setting, symbolizing AI vaccine development.

Jun 9, 2026

AI Vaccine Clears Human Trials, Handing Pharma a New Playbook

A groundbreaking AI-designed vaccine has successfully passed its initial human safety trial, signaling a potential shift in pharmaceutical development.The vaccine, created by the University of Cambridge and its spinout DIOSynVax, demonstrates a novel approach by utilizing AI to analyze global virus surveillance data rather than starting with a known pathogen. This method allowed the AI to identify patterns across various virus variants and develop a vaccine component that human researchers had n
Silhouette of interconnected laboratory instruments

Jun 9, 2026

Scispot Secures $8M to Expand AI-Native Operating Layer for Modern Labs

Scispot has secured $8 million in Series A funding to enhance its AI-native operating layer, aimed at addressing the fragmentation in modern laboratories.The Kitchener-Waterloo-based company, Scispot, has successfully completed a funding round led by Avenue Growth Partners. The funds will be utilized to expand its workforce in product development and AI implementation, as well as to enhance its commercial services globally. Scispot’s platform serves over 100 enterprise labs across various sector
A laboratory notebook and pen on a wooden table in a research setting.

Jun 9, 2026

Why clear AI policy is the new catalyst for Life Sciences R&D

The integration of clear AI policy is becoming essential for advancing research and development in the life sciences sector.Artificial intelligence (AI) is increasingly recognized as a core component in the life sciences, influencing areas such as drug discovery, clinical trial optimization, and regulatory compliance. However, the primary barrier to widespread AI adoption is not technological but rather the lack of clear policy frameworks. These frameworks are crucial for organizations to innova
A minimalist illustration of a stethoscope and a brain symbolizing AI in healthcare.

Jun 9, 2026

Outcome Capital Taps AI Pioneer to Guide Healthcare's Digital Future

Outcome Capital is positioning itself at the forefront of healthcare's digital transformation with the appointment of Dr. David Feygin as Senior Advisor, signaling a pivotal shift towards AI-driven strategies in the sector.Based in Boston, Outcome Capital aims to lead the advisory landscape by integrating deep expertise in artificial intelligence and digital health into its operations. Dr. Feygin, known for his extensive experience in regulated industries, previously served as Chief Digital Heal
Medical imaging equipment in a hospital room during blue hour

Jun 9, 2026

AI in Healthcare Emerges as High-Growth Opportunity, with Market Projected to Reach US$ 146.3 Billion by 2031 - Latest Report by Wissen Research

The AI in healthcare sector is poised for significant growth, with projections indicating an increase from USD 20.2 billion in 2025 to USD 146.3 billion by 2031, reflecting a compound annual growth rate (CAGR) of 39% during this period, as reported by Wissen Research.This expansion is largely attributed to the increasing volume of healthcare data, the rising demand for precision medicine, and the need for improved clinical efficiency. AI applications are becoming integral to various domains, inc
A minimalist illustration of a radiology report with a checkmark, symbolizing workflow efficiency in AI-driven radiology.

Jun 9, 2026

How collaboration advances workflow-native AI

The integration of AI in radiology workflows is advancing significantly with tools like Dragon Copilot and PowerScribe One, which enhance efficiency and report quality for radiologists.Since the introduction of Dragon Copilot, healthcare organizations have been enhancing their AI strategies, particularly in radiology. PowerScribe One, in conjunction with Dragon Copilot, provides a seamless, AI-driven workflow that simplifies report creation and offers in-workflow insights. This integrated approa
Dollar sign with upward arrow representing financial growth in AI IPO

Jun 9, 2026

Gotrade Daily: OpenAI Joins the AI IPO Race

The artificial intelligence (AI) sector is witnessing a significant shift as OpenAI prepares for its initial public offering (IPO), following Anthropic's recent market entry. This development is poised to attract retail investors eager to capitalize on the burgeoning AI landscape.OpenAI is reportedly collaborating with major financial institutions, Goldman Sachs and Morgan Stanley, to facilitate its IPO, with expectations of a listing in 2026. The company's valuation has soared past $850 billion
A stack of financial reports and a calculator on an office desk with a city view

Jun 9, 2026

Relm Insurance Launches ALPHA Policy for Investment Managers Across AI, Biotech, Digital Assets and Other Emerging Sectors

Relm Insurance has unveiled its new ALPHA policy, targeting investment managers in innovative sectors like AI and biotech.On June 9, 2026, Relm Insurance announced the launch of ALPHA, a specialized insurance solution crafted for investment managers engaged in emerging asset classes, including artificial intelligence, biotechnology, and digital assets. This new policy expands upon the previously introduced ALPHAWEB3, which focused on blockchain-related investment strategies. The ALPHA policy aim
A minimalist illustration of a pipette with a droplet, symbolizing scientific experimentation.

Jun 9, 2026

PromptBio Launched All-New Agentic AI Platform For Life Sciences, Turning Scientific Intent Into Executable Experiments

PromptBio has unveiled its innovative Agentic AI Platform, designed to transform scientific intent into actionable experiments, streamlining the research process in life sciences.This new platform integrates conversational AI with a multi-agent orchestration system, allowing researchers to formulate and execute complex analyses using natural language. By automating the design of workflows, data analysis, and interpretation of results, the platform aims to significantly cut down the time and effo
A biopsy sample on a glass slide under a microscope in a dimly lit lab.

Jun 9, 2026

CareDx (CDNA) Valuation Check After Choppy Trading And Growing AI Diagnostics Story

CareDx (CDNA) has garnered attention from investors following fluctuating trading patterns, with the stock showing mixed performance over recent months. While the share price has dipped slightly in the last week, it has demonstrated growth over the past quarter and year.Currently, CareDx's stock is trading below the average analyst price target, raising questions about its valuation. Many analysts suggest that the stock is undervalued, estimating a fair value of $25.80 per share compared to its